The KEYNOTE-966 Investigators, Kelley, R K, Ueno, M, Yoo, C, Finn, R S, Furuse, J, Ren, Z, Yau, T, Klümpen, H-J, Chan, S L, Ozaka, M, Verslype, C, Bouattour, M, Park, J O, Barajas, O, Pelzer, U, Valle, J W, Yu, L, Malhotra, U, Siegel, A B, Edeline, J & Vogel, A 2023, ' Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial ', The Lancet . https://doi.org/10.1016/S0140-6736(23)00727-4 The Lancet The Lancet, 2023, 401 (10391), pp.1853-1865. ⟨10.1016/S0140-6736(23)00727-4⟩ KEYNOTE-966 Investigators 2023, ' Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966) : a randomised, double-blind, placebo-controlled, phase 3 trial ', The Lancet, vol. 401, no. 10391, pp. 1853-1865 . https://doi.org/10.1016/S0140-6736(23)00727-4 The Lancet, 401(10391), 1853-1865. Elsevier Limited
British Journal of Cancer Corrie, P G, Qian, W, Basu, B, Valle, J, Falk, S, Iwuji, C, Wasan, H, Palmer, D, Scott-Brown, M, Wadsley, J, Arif, S, Bridgewater, J, Propper, D, Gillmore, R, Gopinathan, A, Skells, R, Bundi, P, Brais, R, Dalchau, K, Bax, L, Chhabra, A, Machin, A, Dayim, A, McAdam, K, Cummins, S, Wall, L, Ellis, R, Anthoney, A, Evans, J, Ma, Y T, Isherwood, C, Neesse, A, Tuveson, D & Jodrell, D I 2020, ' Scheduling nab-paclitaxel combined with gemcitabine as first line treatment for metastatic pancreatic adenocarcinoma ', BJC, vol. 122, pp. 1760–1768 . https://doi.org/10.1038/s41416-020-0846-2